BYETTA Approved for Expanded Use as First-Line Treatment for Type ...(including fatal and non-fatal hemorrhagi...)

Date:10/30/2009

including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who have severe kidney problems, and should be used with caution in people who have had a kidney transplant. Patients should talk with their healthcare provider if they have severe problems with their stomach, such as delayed emptying of the stomach (gastroparesis) or problems with digesting food. Severe allergic reactions can happen with BYETTA.

The most common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea most commonly happens when first starting BYETTA, but may become less over time.

These are not all the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For Prescribing Information and Medication Guide, visit www.BYETTA.com.

About Amylin and Lilly

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

Through a long-standing commitment to diabetes care, Lilly seeks to provide patients with breakthrough treat
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
2. Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes
3. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
4. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
5. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
6. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
7. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
8. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
9. Clexane(R)/Lovenox(R) Approved in Japan
10. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
11. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer